Abalos Therapeutics
Abalos Therapeutics is a biotechnology company developing a new class of systemically administrable candidates using its unique AdaptInnate approach to trigger precise immune responses from within a patient's tumor.
Classification
Profile
Not yet available.
Funding
Funding details not yet available.
Develops systemically administrable cancer therapies using the unique AdaptInnate approach to trigger precise innate and adaptive immune responses from within tumors.
Patients with cancer requiring novel immunotherapies; potential pharmaceutical partners for drug development and licensing.
Product sales of approved therapies and potential licensing deals for their AdaptInnate platform technology.
Direct sales outreach and partnerships with healthcare providers, supported by a corporate website and clinical trial collaborations.
Academic institutions, specifically the University Duisburg-Essen under the leadership of Prof. Dr. Karl Lang.
R&D costs associated with developing new class of systemically administrable candidates and managing the AdaptInnate platform.
Proprietary AdaptInnate approach, scientific team led by Managing Director Dr. Jörg Vollmer, and IP related to immune response triggering.
Research and development of novel cancer treatments that leverage the AdaptInnate platform to activate patient immune systems against tumors.
Sales-led engagement with healthcare institutions and oncology professionals.
Competes in the oncology immunotherapy space by offering systemically administrable candidates that activate both innate and adaptive immunity.
Need for effective systemic cancer treatments that can precisely activate both innate and adaptive immune responses directly within the tumor microenvironment.
- Accelerate Combination Program - Formalize a co-development deal with a PD-1/PD-L1 leader (e.g., Merck, Bristol-Myers) to generate joint
- The website’s “Therapeutic Approach” page provides detailed mechanistic data and cites peer‑reviewed publication in Cell Reports Medicine—a strong scientific validation[2][3].
- Recent press releases (Nov 2025) confirm that the first patient has been dosed in a Phase 1 trial, indicating that the company is beyond the “pre‑clinical” stage and has achieved a critical de‑risking milestone[6].
No investors recorded yet.